全球慢性冠脉综合征长期结局:国际CLARIFY注册研究洞察
基于CLARIFY前瞻性观察注册研究(2009年11月至2010年6月入组,随访5年),分析32 703例来自45个国家的慢性冠脉综合征患者。主要终点(心血管死亡或非致死性心肌梗死)5年发生率为8.0%(95%CI 7.7-8.3)。既往心肌梗死合并心绞痛患者事件率显著高于无绞痛者(11.8% vs 8.2%,P<0.001),而无心肌梗死患者中两者相似。
要点
- 慢性冠脉综合征患者5年主要终点事件率为8.0%。
- 既往心肌梗死合并心绞痛是易识别的高危亚组。
- 指南推荐二级预防药物处方率高,但高危亚组仍需强化治疗。
核心结论
- 尽管循证二级预防治疗处方率高,既往心肌梗死合并心绞痛患者仍为易识别的高危群体,可能需强化治疗。
研究设计与样本
- 前瞻性观察性CLARIFY注册研究,纳入45个国家32 703例慢性冠脉综合征患者,随访5年。
主要发现
- 主要终点5年发生率为8.0%(95%CI 7.7-8.3),男性8.1%(95%CI 7.8-8.5),女性7.6%(95%CI 7.0-8.3)。
- 主要独立预测因素包括既往心力衰竭住院、当前吸烟、心房颤动、居住在中/南美洲、既往心肌梗死、既往卒中、糖尿病、当前心绞痛和外周动脉疾病。
- 心绞痛与既往心肌梗死存在交互作用(P=0.0016):既往心肌梗死患者中,有心绞痛者主要事件率为11.8%(95%CI 10.9-12.9),无绞痛者为8.2%(95%CI 7.8-8.7),P<0.001。
- 无既往心肌梗死患者中,有心绞痛与无绞痛事件率相似[6.3%(95%CI 5.4-7.3)vs 6.4%(95%CI 5.9-7.0),P>0.99]。
临床怎么用
- 对既往心肌梗死合并心绞痛患者应识别为高危群体,考虑强化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Over the last decades, the profile of chronic coronary syndrome has changed substantially. We aimed to determine characteristics and management of patients with chronic coronary syndrome in the contemporary era, as well as outcomes and their determinants. METHODS AND RESULTS: Data from 32 703 patients (45 countries) with chronic coronary syndrome enrolled in the prospective observational CLARIFY registry (November 2009 to June 2010) with a 5-year follow-up, were analysed. The primary outcome [cardiovascular death or non-fatal myocardial infarction (MI)] 5-year rate was 8.0% [95% confidence interval (CI) 7.7-8.3] overall [male 8.1% (7.8-8.5); female 7.6% (7.0-8.3)]. A cox proportional hazards model showed that the main independent predictors of the primary outcome were prior hospitalization for heart failure, current smoking, atrial fibrillation, living in Central/South America, prior MI, prior stroke, diabetes, current angina, and peripheral artery disease. There was an interaction between angina and prior MI (P = 0.0016); among patients with prior MI, angina was associated with a higher primary event rate [11.8% (95% CI 10.9-12.9) vs. 8.2% (95% CI 7.8-8.7) in patients with no angina, P < 0.001], whereas among patients without prior MI, event rates were similar for patients with [6.3% (95% CI 5.4-7.3)] or without angina [6.4% (95% CI 5.9-7.0)], P > 0.99. Prescription rates of evidence-based secondary prevention therapies were high. CONCLUSION: This description of the spectrum of chronic coronary syndrome patients shows that, despite high rates of prescription of evidence-based therapies, patients with both angina and prior MI are an easily identifiable high-risk group who may deserve intensive treatment. CLINICAL REGISTRY: ISRCTN43070564.
引用
- Sorbets E, Fox KM, Elbez Y, et al. Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J. 2020. PMID: 31504434. doi:10.1093/eurheartj/ehz660
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。